Clinical Trial

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-08-30; most recent amendment 2026-06-30.
Status change: Completed → Active, Not Recruiting 2026-06-30
Status change: Recruiting → Completed 2025-05-05
Status change: Not Yet Recruiting → Recruiting 2022-02-01
Trial Details
NCT Number NCT04535193
Lead Sponsor Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Collaborators: Mount Sinai Hospital, New York
Conditions Cardiovascular Diseases
Enrollment 10 participants
Start Date 2021-11-05
Primary Completion 2025-03-07 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02